Published in Vaccine Weekly, January 14th, 2004
The results were presented at the recent American Society of Hematology annual meeting by the principal investigator on the clinical trial, Johannes Vieweg, MD, associate professor of urology and associate professor of immunology at Duke.
Vieweg's presentation reported that all but one of the patients in the clinical trial evaluated so far showed strong telomerase-specific cellular immune responses, that no patients exhibited any...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly